Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo

Shimoda, Shinya; Ichihara, Hideaki; Matsumoto, Yōko; Ueoka, Ryuichi

doi:10.1016/j.ijpharm.2009.01.011

Cited by 28 publications

(30 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24,25) The tumor volume reached 100-150 mm 3 at day 6 after the inoculation of MDA-MB-453 cells, and then TTZ-LAK and CD3-LAK cells were intravenously administered twice each week for 14 d from day 6. The solid tumors were weighed after anatomizing the mice after 21 d of inoculation of MDA-MB-453 cells.…”

Section: Methodsmentioning

confidence: 99%

Therapeutic Effects of Autologous Lymphocytes Activated with Trastuzumab for Xenograft Mouse Models of Human Breast Cancer

Nakagawa

Matsuoka

Ichihara

et al. 2013

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Trastuzumab (TTZ) is molecular targeted drug used for metastatic breast cancer patients overexpressing human epidermal growth factor receptor 2 (HER2). Therapeutic effects of lymphocytes activated with TTZ (TTZ-LAK). p185 HER2 has partial homology with the epidermal growth factor receptor and shares intrinsic tyrosine kinase activity with that receptor. HER2 overexpressed in human breast cancers correlated with poor clinical outcome in women with breast cancers.1-3) HER2 is known as epidermal growth factor receptor (ErbB) 2 of the tyrosine kinase (TK) receptor, belonging to ErbB growth factor receptor family. There are four members of HER family receptors; epidermal growth factor receptor (EGFR)/ErbB1/ HER1, HER2/ErbB2, HER3/ErbB3, and HER/ErbB4.3) HER family receptors are activated by ligand-induced dimerization, or receptor pairing. Dimerization is a critical step in HER family-mediated signaling, and HER receptors are able to homodimerize or heterodimerize with other HER family members. HER2 is the preferred dimerization partner for all HER family receptors. However, there are no known endogenous ligands that bind to HER2. 4)The extracellular domain of HER2 is in a conformation that is open and ready for dimerization. So, molecules such as monoclonal antibodies would bind to the extracellular domain of HER2 to suppress those activity. Several monoclonal antibodies (mAbs) directed against HER2 ectodomain that specifically inhibit the growth of tumor cell lines overexpressing HER2 have been developed. 5) Trastuzumab (TTZ) is a humanized immunoglobulin G1 kappa (IgG1κ) light chain mAb in which the complementary-determining regions (CDR) of a HER2-specific mouse mAb were joined to in human immunoglobulin variable regions.5) TTZ binds to the domain IV of the extracellular segment of the HER2/neu receptor. Because TTZ belong to IgG1, its effects may be related to Fab (antigen binding fragment) or Fc (crystallizable fragment) regions.6) It has been reported that antibody-dependent cellular cytotoxicity (ADCC) plays an important role in the antitumor activity of TTZ. 7) Although the mechanisms underlying the action of TTZ are still not fully understood, inhibitory effects of TTZ by cell cycle arrest in G1 and induction of apoptosis on the growth of HER2-positive breast cancer cells in vitro have been reported.8) The combination chemotherapy with TTZ has been shown to improve survival for women with HER2-overexpressing metastatic breast cancer patients. [9][10][11] However, there were severe side-effects in combination chemotherapy. 1,6,12,13) On the other hand, immunotherapy using lymphocyte stimulated with immunomodulators such as cytokines was noted in cancer therapy as attractive approach, since there is no serious side effects in immunotherapy. Significant prolongation in survival and disease free period in group of immunotherapy compared with no-treatment group have been reported. 14)Yoshida et al. have studied metastasis mechanism of cancer cells 15,16) and for clinical applications of immunotherapy using CD3-a...

show abstract

Section: Methodsmentioning

confidence: 99%

Therapeutic Effects of Autologous Lymphocytes Activated with Trastuzumab for Xenograft Mouse Models of Human Breast Cancer

Nakagawa

Matsuoka

Ichihara

et al. 2013

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

show abstract

“…[24][25][26][27] The particle size of HL-n was measured by dynamic light scattering measurements. 22 HL-n had hydrodynamic mean diameters of between 60 and 90 nm with a single and narrow range of size distribution ( Figure S1, Supporting Information).…”

Section: Acs Medicinal Chemistry Lettersmentioning

confidence: 99%

“…HL-n potently inhibited the growth of these cancer cells at IC 50 How do HL-n inhibit the growth of cancer cells? We have already reported that hybrid liposomes composed of DMPC and polyoxyethylene(n) alkyl ethers induced apoptosis in cancer cells such as liver cancer, 30 lung cancer, 22 breast cancer, 25 colon cancer, 28 lymphoma, 27 and primary effusion lymphoma. 31 In the present study, we confirmed the induction of apoptosis by HL-n in cancer cells on the basis of the TUNEL method using confocal laser microscopy.…”

Section: Acs Medicinal Chemistry Lettersmentioning

confidence: 99%

“…20 On the other hand, we have reported that hybrid liposomes (HL-n) composed of DMPC and polyoxyethylene(n) dodecyl ethers (C 12 (EO) n ) without any drugs inhibited the proliferation of various cancer cells along with apoptosis in vitro 21-23 and in vivo. 24,25 Furthermore, successful clinical chemotherapy with drug-free HL-n to patients with lymphoma has been reported. 26,27 Significantly, we …”

mentioning

confidence: 99%

See 1 more Smart Citation

Membrane-Targeted Nanotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis

Komizu

Nakata

Goto

et al. 2011

ACS Med. Chem. Lett.

Self Cite

View full text Add to dashboard Cite

Hybrid liposomes are nanosized liposomal particles and can be prepared by sonication of vesicular and micellar molecules in a buffer solution. In this study, we obtained the first successful experiment resulting in a good correlation between inhibitory effects of hybrid liposomes on the growth of various tumor cells and the membrane fluidity of tumor cells (plasma membranes). The results indicated that hybrid liposomes could provide the possibility of novel membrane-targeted nanotherapy for intractable cancers.

show abstract

“…5 On the other hand, hybrid liposomes composed of DMPC and polyoxyethylene(n) alkyl ethers without any drugs demonstrated remarkable inhibitory effects on the growth of various tumor cells in vitro [6][7][8] and in vivo. [9][10][11][12] In addition, it has been demonstrated that hybrid liposomes could induce apoptotic cell death in leukemia, 13 hepatoma, 7 lung cancer, 14 breast cancer, 8 and primary effusion lymphoma cells. 15 With respect to colon cancer cell lines, hybrid liposomes induced apoptosis in human colon adenocarcinoma WiDr 16 and mouse colon carcinoma Colon26 cells in vitro.…”

Section: Introductionmentioning

confidence: 99%

Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis

Komizu¹,

Ueoka²,

Goto³

et al. 2011

IJN

Self Cite

View full text Add to dashboard Cite

Background Hybrid liposomes can be prepared by simply sonicating a mixture of vesicular and micellar molecules in buffer solutions. In this study, we investigated the effects of hybrid liposomes on the growth of human colon cancer cells in vitro. Methods Hybrid liposomes (HL-n, n = 21, 23, 25) composed of L-α-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene( n ) dodecyl ethers (C 12 (EO) n , n = 21, 23, 25) were prepared by the sonication method and their inhibitory effects on growth of human colon cancer HCT116 cells were examined in vitro. Results Significant growth inhibition of HCT116 cells was observed in the presence of HL-n. The fifty percent inhibitory concentration (IC 50 ) of HL-n was less than half that of DMPC liposomes. Furthermore, fluorescence microscopic and flow cytometric analyses indicated that the markedly inhibitory effects of HL-n on the growth of HCT116 cells could be attained through the induction of cell cycle arrest at the G 0 /G 1 phase along with apoptotic cell death. Conclusion It was found for the first time that HL-n can induce both cell cycle arrest and apoptosis in colon cancer cells. The findings in this study should contribute to novel chemotherapy for colon cancer.

show abstract

Chemotherapy with hybrid liposomes for human breast tumors along with apoptosis in vivo

Cited by 28 publications

References 32 publications

Therapeutic Effects of Autologous Lymphocytes Activated with Trastuzumab for Xenograft Mouse Models of Human Breast Cancer

Therapeutic Effects of Autologous Lymphocytes Activated with Trastuzumab for Xenograft Mouse Models of Human Breast Cancer

Membrane-Targeted Nanotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis

Remarkable inhibitory effects of hybrid liposomes on growth of human colon cancer cells through induction of cell cycle arrest along with apoptosis

Contact Info

Product

Resources

About